TRAW - Traws Pharma EV/EBITDA Multiple

Corporate company logo of Traws Pharma Inc (TRAW)

Traws Pharma, Inc. (TRAW) develops oral treatments for influenza and COVID-19, generating revenue through government contracts and licenses. This daily price chart on GURU.Markets shows an EV/EBITDA of 0.00. The business's financial strength is underscored by a lack of debt and robust patent protection. Diversified international logistics routes guarantee supply stability, completely eliminating raw material disruptions for production.

TRAW Traws Therapeutics: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/12/2026

Analytical breakdowns for Traws Pharma, Inc.

- stock price and consensus target price:
Stock Quotes Traws Pharma|TRAW - Price Target Chart
- market capitalization statistics:
Market Capitalization TRAW|TRAW - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Traws Pharma|TRAW - Accounting Value of Company|Market Cap to Net Assets Ratio trawspharma.com|TRAW - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Traws Pharma, Inc.|TRAW - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Traws Pharma|TRAW - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio TRAW|TRAW - Company Long-Term Loans and Borrowings|Company Short-Term Debts Traws Pharma|Quick Liquidity Indicator trawspharma.com
- business earnings and investment ratios data:
TRAW - Net Income|Expected Profit Traws Pharma, Inc.|TRAW - Business Payback Period|Projected Price to Earnings Traws Pharma|TRAW - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TRAW|TRAW - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Traws Pharma|TRAW - Earnings per share for the trailing year|Quarterly EPS earnings growth trawspharma.com|TRAW - Earnings growth in current year|Net earnings per share growth forecast for next year Traws Pharma, Inc.
General company analysis:TRAW (Traws Therapeutics)
Original product of Traws Pharma Inc

Traws Pharma, Inc. (TRAW) is strengthening its position in the biotechnology sector, creating long-term sales potential through the development of proprietary antiviral drugs. By analyzing the EV/EBITDA multiple trend, an investor compares the total enterprise value with operating profit, which allows for an assessment of the company's resilience to debt obligations and determines the asset's real margin of safety amid market volatility.

Key competitors

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|Enanta Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio INO (Inovio Pharmaceuticals, Inc.)|HLVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation KLRS (Kalaris Tx)|DYAI: EV/EBITDA Multiple|NanoViricides (NNVC) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio TLPH|Enterprise Value to EBITDA Ratio Cocrystal Pharma Inc (COCP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Corp|AlloVir - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VBIV|VIRI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VXRT